GlassScriptPhysician profile
Jeffrey Lafond
NPI 1780973081
$11,273.95
in general payments reported to CMS, 2019-2025
38 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $682 · 2021: $1,501 · 2022: $1,618 · 2023: $2,427 · 2024: $2,280 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,512.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,951.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,648.89 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,232.52 | 2020-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $764.96 | 2020-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $759.52 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $587.93 | 2022-2025 | |
| Celgene Corporation | $421.84 | 2021-2024 | Zeposia |
| Pfizer INC. | $414.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $213.04 | 2019-2024 | Dificid |
| Ardelyx, INC. | $175.96 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $117.54 | 2019-2024 | Suflave, Sutab |
| Ethicon US, LLC | $102.00 | 2023 | Linx Reflux Management System |
| Celltrion USA INC. | $99.64 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $77.96 | 2020-2024 | |
| Nestle Healthcare Nutrition INC. | $61.01 | 2021-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.59 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $54.37 | 2020-2021 | |
| Gilead Sciences, INC. | $52.32 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $50.43 | 2024-2025 | Voquezna |
| Apollo Endosurgery US INC | $49.00 | 2022 | |
| Shionogi INC | $46.31 | 2019 | |
| Organon LLC | $31.79 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $28.36 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $27.92 | 2024 | Iqirvo |
| Allergan, INC. | $26.29 | 2019-2020 | |
| Amgen INC. | $24.25 | 2023 | Avsola, Amjevita |
| Lilly USA, LLC | $22.71 | 2025 | Omvoh |
| Ucb, INC. | $19.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.28 | 2023 | Dupixent |
| Intra-Sana Laboratories | $17.33 | 2022 | |
| Mylan Institutional INC. | $16.80 | 2023 | Hulio |
| W. L. Gore & Associates, INC. | $16.70 | 2021 | |
| Boston Scientific Corporation | $16.04 | 2022 | |
| Intercept Pharmaceuticals, INC. | $15.82 | 2019 | |
| Olympus America INC. | $14.85 | 2024 | Single Use Electrosurgical Snare Sd-400 |
| Bard Peripheral Vascular, INC. | $14.33 | 2021 | |
| Fresenius Kabi USA, LLC | $14.01 | 2024 | Idacio |
| Concordia Pharmaceuticals INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lafond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.